AR and renal carcinoma: This regulation is likely direct, as AR is specifically recruited to the DHX9 promoter in LNCaP cells, as previously reported in renal carcinoma cells [22], while AR inhibition under androgen deprivation or enzalutamide treatment caused repression of DHX9 expression.